SAFC opens US$30m HPAPI facility
The expansion significantly increases SAFC\'s capacity to produce commercial scale HPAPIs
SAFC, a division of the Sigma-Aldrich life science group, has opened a US$30m expansion to its Madison manufacturing facility in Verona, Wisconsin, US.
The 51,000ft2 expansion significantly increases SAFC’s capacity to produce commercial scale high potency active pharmaceutical ingredients (HPAPIs). It will ultimately result in 45–50 new jobs.
The new facility complements SAFC's existing 63,000ft2 HPAPI site in Madison and houses commercial scale reactors capable of producing batch sizes up to 4,000 litres. Built to support pharmaceutical manufacturers with their Phase III and commercial HPAPI needs, the Verona plant has the same facility design and containment engineering as the Safebridge-certified Madison facility on a larger scale.
The site adheres to Category IV standards and includes development laboratories, a 150-litre mini-processing plant and two large-scale cGMP manufacturing suites. Specially designed quality control laboratories, a potent compound packaging area and warehouse and office space are also available in the building.
‘With the high potency market continuing to experience double-digit growth and ongoing significant advances in clinical pharmacology and oncology, there is a significant need for the large-scale production of HPAPIs,’ said Gilles Cottier, president of SAFC.
‘This new facility represents a significant step towards addressing that market demand and supports SAFC's desire to maintain a leadership position in commercial scale high potency manufacture.’
